5 recruiting, 4 completed, 2 not yet recruiting. 6 Phase 1, 5 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 3, Recruiting 2, Not yet recruiting 1 |
| Phase 2 | 5 | Recruiting 3, Completed 2 |
| Phase 3 | 2 | Not yet recruiting 1, Recruiting 1 |
Follow Shanghai Jiatan Pharmatech Co., Ltd: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase III Clinical Study of WX390 Combined With Toripalimab Versus Investigator's Choice of Therapy in Patients With Recurrent or Metastatic Cervical Cancer Who Have Failed Prior Platinum-Based Treatment WX390 1.1mg + Toripalimab 240mg, Investigator's Choice of Chemotherapy - Cervical Cancer Metastatic | Phase 3 | Not yet recruiting | Shanghai Jiatan Pharmatech Co., Ltd | 440 | 2026-02-28 | 2026-02-06 |
| Drug-Drug Interaction and Food Effect of Sudapyridine(WX-081) With Itraconazole and Rifampin in Healthy Chinese Adults Sudapyridine, Itraconazole, Rifampin - Rifampicin-Resistant Pulmonary Tuberculosis Patients | Phase 1 | Not yet recruiting | Shanghai Jiatan Pharmatech Co., Ltd | 16 | 2025-05-12 | 2025-02-12 |
| Pharmacokinetic Study of Sudapyridine（WX-081）in Healthy Chinese Subjects [U-14C] WX-081 - TB | Phase 1 | Recruiting | Shanghai Jiatan Pharmatech Co., Ltd | 10 | 2024-09-04 | 2024-11-22 |
| A Study of WX390 Combined With Toripalimab in Patients With Advanced Gastric-type Endocervical Adenocarcinoma With STK11 Mutations WX390, Toripalimab - Gastric Type Adenocarcinoma (GAS) With STK11 Mutation | Phase 2 | Recruiting | Shanghai Jiatan Pharmatech Co., Ltd | 20 | 2023-08-25 | 2024-12-10 |
| A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors WX390, Toripalimab - Solid Tumor | Phase 1 / Phase 2 | Recruiting | Shanghai Jiatan Pharmatech Co., Ltd | 100 | 2022-11-18 | 2024-11-25 |
| A Phase III Study of Oral Sudapyridine (WX-081) Tablets in Rifampicin-Resistant Pulmonary Tuberculosis Patients Sudapyridine, Bedaquiline - Rifampin-Resistant Pulmonary Tuberculosis, Tuberculosis, Multidrug-Resistant (MDR-TB) | Phase 3 | Recruiting | Shanghai Jiatan Pharmatech Co., Ltd | 450 | 2022-09-02 | 2025-06-29 |
| A Study of WX390 in Patients With Advanced Solid Tumors With PIK3CA Mutations WX390 - PIK3CA Mutation-Related Tumors | Phase 1 / Phase 2 | Completed | Shanghai Jiatan Pharmatech Co., Ltd | 38 | 2021-06-03 | 2023-11-15 |
| A Study of WX390 in Patients With Advanced Solid Tumors WX390 - Solid Tumor | Phase 2 | Recruiting | Shanghai Jiatan Pharmatech Co., Ltd | 70 | 2021-05-11 | 2024-11-19 |
| Evaluation of Early Bactericidal Activity and Safety in Pulmonary Tuberculosis With WX-081 WX-081, Bedaquiline, Standard treatment - Pulmonary Tuberculosis | Phase 2 | Completed | Shanghai Jiatan Pharmatech Co., Ltd | 99 | 2020-10-16 | 2023-09-11 |
| Sudapyridine (WX-081) in Healthy Volunteers Sudapyridine 30mg, Sudapyridine 100mg SAD, Sudapyridine 200mg SAD - Healthy | Phase 1 | Completed | Shanghai Jiatan Pharmatech Co., Ltd | 82 | 2019-02-13 | 2023-11-07 |
| A Study of WXFL10030390 in Patients With Advanced Solid Tumors or Lymphoma WXFL10030390 - Advanced Cancer | Phase 1 | Completed | Shanghai Jiatan Pharmatech Co., Ltd | 82 | 2018-10-25 | 2023-04-18 |
Tuberculosis (2) · Tuberculosis, Pulmonary (2) · Hereditary Sensory and Autonomic Neuropathies (1) · Tuberculosis, Multidrug-Resistant (1)
sudapyridine (5) · toripalimab (3) · bedaquiline (2) · Itraconazole (1) · Rifampin (1) · Sagittal Abdominal Diameter (1) · mycophenolic adenine dinucleotide (1)
China (9)
Jin Li, Doctor (1) · Jin Li, PhD (1) · Naihui Chu, Ph.D (1) · Song AiYun, MD (1) · Xiaohua Wu, PhD (1) · Yanhua Ding, PhD (1) · Yu Kang, PhD (1) · Yun Liu (1)